Published in JAMA on April 02, 2008
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe (2009) 4.55
Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One (2008) 2.12
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2010) 1.70
A policy approach to the development of molecular diagnostic tests. Nat Biotechnol (2010) 1.46
The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. BMC Med Genomics (2008) 1.41
Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol (2010) 1.37
Advances in translational bioinformatics: computational approaches for the hunting of disease genes. Brief Bioinform (2009) 1.27
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18
Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol (2010) 1.18
Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer (2010) 1.16
Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol (2012) 1.16
Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol (2010) 1.05
Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles. BMC Genomics (2010) 1.04
Can survival prediction be improved by merging gene expression data sets? PLoS One (2009) 1.04
Overall expression of beta-catenin outperforms its nuclear accumulation in predicting outcomes of colorectal cancers. World J Gastroenterol (2008) 1.03
Gene interaction enrichment and network analysis to identify dysregulated pathways and their interactions in complex diseases. BMC Syst Biol (2012) 0.99
Comparison of data-merging methods with SVM attribute selection and classification in breast cancer gene expression. BMC Bioinformatics (2012) 0.93
Prevalence of scientific misconduct among a group of researchers in Nigeria. Dev World Bioeth (2012) 0.92
Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis (2009) 0.92
Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics. OMICS (2012) 0.86
Biclustering reveals breast cancer tumour subgroups with common clinical features and improves prediction of disease recurrence. BMC Genomics (2013) 0.85
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform. BMC Med Genomics (2010) 0.84
Role for transcription factor TFII-I in the suppression of SSeCKS/Gravin/Akap12 transcription by Src. Int J Cancer (2011) 0.84
Assessment of kidney organ quality and prediction of outcome at time of transplantation. Semin Immunopathol (2011) 0.82
Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS One (2010) 0.82
A radiation-derived gene expression signature predicts clinical outcome for breast cancer patients. Radiat Res (2009) 0.82
Approaches towards expression profiling the response to treatment. Breast Cancer Res (2008) 0.81
Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma. Tumour Biol (2012) 0.81
Documenting biospecimen conditions in reports of studies. JAMA (2008) 0.80
Sense-antisense gene-pairs in breast cancer and associated pathological pathways. Oncotarget (2015) 0.79
Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation. Endocr Relat Cancer (2013) 0.79
Global transcriptomic profiling using small volumes of whole blood: a cost-effective method for translational genomic biomarker identification in small animals. Int J Mol Sci (2011) 0.77
Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmgenomics Pers Med (2010) 0.77
Drosophila as a tool for personalized medicine: a primer. Per Med (2010) 0.77
Knowledge driven decomposition of tumor expression profiles. BMC Bioinformatics (2009) 0.77
A hybrid approach of gene sets and single genes for the prediction of survival risks with gene expression data. PLoS One (2015) 0.75
Use of gene signatures to improve risk estimation in cancer. JAMA (2008) 0.75
Findings of Research Misconduct. Fed Regist (2015) 0.75
Findings of research misconduct. NIH Guide Grants Contracts (2015) 0.75
Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. Sci Rep (2016) 0.75
Molecular genetics complexity impeding research progress in breast and ovarian cancers. Mol Clin Oncol (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe (2009) 4.55
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol (2005) 2.88
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet (2007) 2.57
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet (2010) 2.34
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25
An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23
New targets for triple-negative breast cancer. Oncology (Williston Park) (2013) 2.23
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol (2009) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol (2009) 2.21
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17
General conditions for predictivity in learning theory. Nature (2004) 2.16
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
Modeling cancer progression via pathway dependencies. PLoS Comput Biol (2008) 2.12
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
The Biomedical Resource Ontology (BRO) to enable resource discovery in clinical and translational research. J Biomed Inform (2010) 2.10
Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genet (2011) 2.10
Use of molecular biomarkers to inform adjuvant therapy for colon cancer. Oncology (Williston Park) (2013) 2.07
Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet (2011) 2.06
Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies. Am J Pathol (2005) 2.05
Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. Drug Discov Today (2002) 2.05
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One (2011) 2.02
Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet (2008) 1.92
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 1.90